Decitabine

PSA Progression

Roswell Park Cancer InstituteSmall moleculePhase 1/2Dormant

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 95/ 100

Competitive context

10 Active assets in the PSA Progression cohort.

Asset / Sponsor	Phase	Rating
Enzalutamide Roswell Park Cancer Institute	Phase 2	BB
Cyclophosphamide Barbara Ann Karmanos Cancer Institute	Phase 2	B
Carboplatin University of Washington	Phase 2	B
68GA-NEOBOMB1 Andrei Iagaru	Phase 2	B
Psma-Hbed-Cc Jonsson Comprehensive Cancer Center	Phase 2	B

View all 20 →

Same molecule, other indications

Decitabine is also rated in:

disease related to hematopoietic stem cell transplantDormant

BBB

Indicative ·

72 / 100

acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant

BB

Indicative ·

70 / 100

acute myeloid leukemiaDormant

BB

Indicative ·

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.